0.34
+2.03%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Soligenix
From its filings with the US Securities and Exchange Commission
Soligenix is based in Princeton, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SNGX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported revenue of $119,371.
We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions.
Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy (“PDT”), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the first Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study and agreement from the European Medicines Agency (“EMA”) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ in the treatment of CTCL patients with early-stage disease, we began patient enrollment during December 2024 for the second Phase 3 study called “FLASH2” (Fluorescent Light Activated Synthetic Hypericin 2). We anticipate top-line results in the second half of 2026. Upon successful completion of the Phase 3 FLASH2 study, regulatory approval will be sought to support potential commercialization worldwide.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Apr 1994
- Employees
- 13
- Website
- soligenix.com ↗
- Head office
- 29 EMMONS DRIVE, PRINCETON, NJ, 08540
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Christopher SchaberChairman of the Board, Chief Executive Officer and President, since 2006$832,626
- Mr. Jonathan GuarinoChief Financial Officer, Senior Vice President, Corporate Secretary$399,176
- Dr. Oreola DoniniSenior Vice President, Chief Scientific Officer$432,105
- Dr. Richard StraubeSenior Vice President and Chief Medical Officer$268,680
- Mr. Gregg LapointeIndependent Director$77,500
- Ms. Diane ParksIndependent Director$70,000
- Dr. Robert RubinIndependent Director$80,000
- Dr. Jerome ZeldisIndependent Director$72,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Late-stage biopharmaceutical company with 15 employees focused on rare disease treatments.
- Specialized BioTherapeutics segment develops SGX301 for cutaneous T-cell lymphoma treatment.
- Public Health Solutions segment includes RiVax ricin toxin vaccine candidate and SGX943 for infectious diseases.
Weaknesses
- Headquartered in Princeton, New Jersey with only 15 employees.
- Limited business segments with only two operational divisions.
- Employees number 15, which is small for a late-stage biopharmaceutical company.
Opportunities
- RiVax vaccine candidate for ricin toxin presents public health opportunity.
- SGX943 therapeutic candidate addresses antibiotic-resistant disease challenges.
- CTCL treatment with SGX301 offers market opportunity in rare diseases.
Threats
- RiVax vaccine candidate faces competition in public health solutions.
- SGX943 therapeutic candidate encounters challenges in infectious disease treatment.
- CTCL treatment with SGX301 faces regulatory hurdles in rare disease markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.